2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120381
    PD 136450 139067-52-0 98%
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats.
    PD 136450
  • HY-120386
    LY382884 211566-75-5 98%
    LY382884 is a selective antagonist for GluR5 kainate receptor. LY382884 prevents the induction of NMDA receptor independent long-term potentiation (LTP).
    LY382884
  • HY-120396
    LY 293284 141318-62-9 98%
    LY 293284 is a potent and selective 5-HT1A receptor agonist. LY 293284 results in a significant drop in core temperature and consumes more food in cholestasis rat induced by bile duct resection.
    LY 293284
  • HY-120419
    PF9601N 133845-63-3 99.85%
    PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity. PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PF9601N
  • HY-120428
    VU0410425 1341167-72-3 98%
    VU0410425 is an mGlu1 negative allosteric modulator. VU0410425 exhibits potent inhibitory activity for rat mGlu1 with an IC50 value of 140 nM. VU0410425 can be used for the research of central nervous system disorders.
    VU0410425
  • HY-120456
    SR16835 1207195-45-6 98%
    SR16835 has high affinity for both NOPr and MOPr, with full agonist activity for NOPr and partial agonist activity for MOPr. SR16835 has no analgesic effect.
    SR16835
  • HY-120474
    Ro 23-0364 98601-60-6 98%
    Ro 23-0364 is an oral active imidazobenzodiazepine agent with mixed benzodiazepine. Ro 23-0364 shows sedative and can be used for study of neurological disease.
    Ro 23-0364
  • HY-120498
    RS-64459-193 123882-89-3 98%
    RS-64459-193 is a 5-HT1A receptor partial agonist with a Ki of 24.9 nM. RS-64459-193 also shows high affinity for 5-HT2C, 5-HT2A and 5-HT7 with pKi values of 6.87, 7.02, and 7.18, respectively. RS-64459-193 is almost devoid of activity at the m 5-HT3 receptor.
    RS-64459-193
  • HY-120521
    Urodilatin 115966-23-9 98%
    Urodilatin is an analogue of ANF-(99-126). Urodilatin is a diuretic-natriuretic regulatory peptide. Urodilatin can be used for research of acute renal failure, congestive heart failure, and bronchial asthma, etc.
    Urodilatin
  • HY-120523
    UBP646 1333213-35-6 98%
    UBP646 is a potent GluN1/GluN2D receptors potentiator, and also potentiates the other three subtypes, GluN1/GluN2A, GluN1/GluN2B, and GluN1/GluN2C receptors.
    UBP646
  • HY-120524
    CGP 31358 125652-47-3 98%
    CGP 31358 is an anticonvulsant agent that binds to a site on the NMDA receptor complex that is coupled to both the transmitter recognition site and to the channel domain. CGP 31358 inhibits the binding of L-Glutamate to the NMDA receptor complex with an IC50 of 53 μM.
    CGP 31358
  • HY-120527
    VU0463841 1439095-16-5 98%
    VU0463841 is a potent, selective and brain-penetrant mGlu5 negative allosteric modulator (NAM) with an IC50 of 13 nM. VU0463841 is ineffective against mGlu1-4 and mGlu7-8. VU0463841 has the potential for the Cocaine addiction research.
    VU0463841
  • HY-120560
    OMDM169 130193-44-1 98%
    OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM.
    OMDM169
  • HY-120564
    BMS-763534 1188407-40-0 98%
    BMS-763534 is a CRF1 antagonist that inhibits neurological disorders such as depression and anxiety..
    BMS-763534
  • HY-120576
    ML169 1222878-02-5 98%
    ML169 (VU0405652) is a potent, selective and brain penetrant positive allosteric modulator (PAM) of M1 mAChR, with an EC50 of 1.38 µM. ML169 is a MLPCN probe and can be used for Alzheimer’s disease.
    ML169
  • HY-120609
    BMS-902483 1192810-88-0 98%
    BMS-902483 is a quinuclidine-containing spirooxazolidine that is a partial agonist of the α7 nicotinic acetylcholine receptor (nAChR). BMS-902483 improves cognitive ability in preclinical rodent models..
    BMS-902483
  • HY-120623
    BMS-284640 230640-88-7 98%
    BMS-284640 is a synthetic sodium hydrogen exchange isomer-1 (NHE-1) inhibitor. BMS-284640 has a more than 380-fold higher NHE-1 inhibitory activity (IC50: 9 nM) compared to cariporide (HY-19693) and is more selective for NHE-1 over NHE-2 (IC50: 1.8 μM) and NHE-5 (IC50: 3.36 μM). BMS-284640 and its analogs also exhibit enhanced oral bioavailability and prolonged plasma half-life in rats..
    BMS-284640
  • HY-120662
    GSK1331268 1207197-70-3 98%
    GSK1331268 is a selective, orally active agonist for mGluR2 with a pEC50 of 6.9. GSK1331268 exhibits good blood-brain barrier penetration. GSK1331268 regulates glutamate signaling, and can be used in research of neurodegenerative and neuropsychiatric diseases.
    GSK1331268
  • HY-120679
    XK469 157435-10-4 98%
    XK469 is an analog of the herbicide assure. XK469 downregulation growth arrest-specific 2 (GAS2) gene expression. XK469 has antitumor activity.
    XK469
  • HY-120682
    UH-AH 37 120382-14-1 98%
    UH-AH 37 is a muscarinic (mAChR) antagonist. UH-AH 37 exhibits a higher potency in inhibiting muscarinic responses in intestinal tissue than cardiac tissue.
    UH-AH 37
Cat. No. Product Name / Synonyms Application Reactivity